In two retrospective cohorts of patients with advanced stage HCC treated with PD-(L)1-targeted immunotherapy (n = 130 and n = 118, respectively), those with NAFLD/NASH-related HCC had a significantly shorter survival than patients with any other etiology.79 The gene discussed is CD274; the disease is hepatocellular carcinoma.